Methyl 4-[1-[3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]piperidin-3-yl]-2-(trifluoromethyl)benzoate
C24H23F3N4O3 — CID 176562156
Data last refreshed: (MolForge compound catalog, from PubChem)
About Methyl 4-[1-[3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]piperidin-3-yl]-2-(trifluoromethyl)benzoate
Methyl 4-[1-[3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]piperidin-3-yl]-2-(trifluoromethyl)benzoate (PubChem CID 176562156) has the molecular formula C24H23F3N4O3 and a molecular weight of 472.47 g/mol. Its IUPAC name is methyl 4-[1-[3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]piperidin-3-yl]-2-(trifluoromethyl)benzoate.
Molecular Properties
| Compound Name | Methyl 4-[1-[3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]piperidin-3-yl]-2-(trifluoromethyl)benzoate |
|---|---|
| PubChem CID | 176562156 |
| Molecular Formula | C24H23F3N4O3 |
| Molecular Weight | 472.47 g/mol |
| Exact Mass | 472.17 |
| IUPAC Name | methyl 4-[1-[3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]piperidin-3-yl]-2-(trifluoromethyl)benzoate |
| SMILES | COC(=O)c1ccc(C2CCCN(c3cc(-c4ccccc4O)nnc3N)C2)cc1C(F)(F)F |
| InChI | InChI=1S/C24H23F3N4O3/c1-34-23(33)16-9-8-14(11-18(16)24(25,26)27)15-5-4-10-31(13-15)20-12-19(29-30-22(20)28)17-6-2-3-7-21(17)32/h2-3,6-9,11-12,15,32H,4-5,10,13H2,1H3,(H2,28,30) |
| InChIKey | WVIRLSXRSZEOAO-UHFFFAOYSA-N |
| XLogP | 4.62 |
| TPSA | 101.57 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 34 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 472.47 |
| LogP ≤ 5 | 4.62 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 176562156 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.